Non-Muscle Invasive Bladder Cancer: Difference between revisions
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
| Line 232: | Line 232: | ||
*# '''<span style="color:#0000ff">I</span><span style="color:#ff0000">mmunosuppressed and immunocompromised patients</span>''' | *# '''<span style="color:#0000ff">I</span><span style="color:#ff0000">mmunosuppressed and immunocompromised patients</span>''' | ||
*#* '''Small series suggest this may not be an absolute contraindication''' | *#* '''Small series suggest this may not be an absolute contraindication''' | ||
*# '''<span style="color:#0000ff">T<span style="color:#ff0000">URBT, immediately after resection</span> due to risk of intravasation and septic death''' | *# '''<span style="color:#0000ff">T</span><span style="color:#ff0000">URBT, immediately after resection</span> due to risk of intravasation and septic death''' | ||
*# '''<span style="color:#0000ff">I</span><span style="color:#ff0000">ncontinence (total)</span>''' | *# '''<span style="color:#0000ff">I</span><span style="color:#ff0000">ncontinence (total)</span>''' | ||
*# '''<span style="color:#0000ff">T</span><span style="color:#ff0000">raumatic catheterization;</span> intravasation risk''' | *# '''<span style="color:#0000ff">T</span><span style="color:#ff0000">raumatic catheterization;</span> intravasation risk''' | ||